U.S. flag

An official website of the United States government

Filters

See more specimen types...
See more states

Other countries

See more countries

Results: 1 to 20 of 76

Tests names and labsConditionsGenes, analytes, and microbesMethods

Spinocerebellar Ataxia Panel

Mayo Clinic Laboratories Mayo Clinic
United States
55
  • T Targeted variant analysis

Spinocerebellar Ataxia Panel (SCA1,2,3,6, and 7)

Center for Genetics at Saint Francis Saint Francis Hospital
United States
55
  • T Targeted variant analysis

SCA Panel (SCA1, 2, 3, 6, 7) test

Neurogenetics Department Cyprus Institute of Neurology and Genetics
Cyprus
55
  • T Targeted variant analysis

Ataxin 2 (ATXN2) gene CAG triplet repeat test

Neurogenetics Department Cyprus Institute of Neurology and Genetics
Cyprus
11
  • T Targeted variant analysis

Amyotrophic Lateral Sclerosis (ALS) / Dementia Panel

Centogene US, LLC - The Rare Disease Company
United States
6466
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

Ataxia / Spastic Paraplegia Comprehensive Panel

Centogene US, LLC - The Rare Disease Company
United States
451452
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

Ataxia Repeat Expansion Panel

Centogene US, LLC - The Rare Disease Company
United States
1313
  • T Targeted variant analysis

ATXN2 - Repeat expansion analysis

Centogene US, LLC - The Rare Disease Company
United States
21
  • T Targeted variant analysis

ATXN2 - Repeat expansion analysis

Centogene AG - the Rare Disease Company
Germany
21
  • T Targeted variant analysis

Amyotrophic Lateral Sclerosis (ALS) / Dementia Panel

Centogene AG - the Rare Disease Company
Germany
6466
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

Ataxia / Spastic Paraplegia Comprehensive Panel

Centogene AG - the Rare Disease Company
Germany
451452
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

Ataxia Repeat Expansion Panel

Centogene AG - the Rare Disease Company
Germany
1313
  • T Targeted variant analysis

Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) Panel

PreventionGenetics
United States
4840
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

Amyotrophic Lateral Sclerosis (ALS) Panel

PreventionGenetics
United States
3633
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

Spinocerebellar Ataxia Type 2 via the ATXN2 CAG Repeat Expansion

PreventionGenetics
United States
21
  • T Targeted variant analysis

Amyotrophic lateral sclerosis, susceptibility to, 13, 183090, Autosomal dominant (Spinocerebellar ataxia type 2) (ATXN2 gene) (Sequence Analysis-All Coding Exons) (Postnatal)

Intergen Genetic Diagnosis and Research Centre
Turkey
11
  • C Sequence analysis of the entire coding region

Spinocerebellar ataxia 2, 183090, Autosomal dominant (Spinocerebellar ataxia type 2) (ATXN2 gene) (Sequence Analysis-All Coding Exons) (Postnatal)

Intergen Genetic Diagnosis and Research Centre
Turkey
11
  • C Sequence analysis of the entire coding region

Genomic UnityⓇ Ataxia Repeat Expansion Analysis (STR analysis of 12 loci)

Variantyx, Inc.
United States
1212
  • D Deletion/duplication analysis
  • X Mutation scanning of select exons
  • C Sequence analysis of the entire coding region

Genomic UnityⓇ Comprehensive Ataxia Analysis (includes STR analysis of 12 loci)

Variantyx, Inc.
United States
5252
  • D Deletion/duplication analysis
  • X Mutation scanning of select exons
  • C Sequence analysis of the entire coding region

Spinocerebellar ataxia type 2 presymptomatic testing

Genetics Service Unit National Institute of Biomedical Genomics
India
11
  • T Targeted variant analysis

Results: 1 to 20 of 76

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.